Morgan Stanley Hutchmed (China) LTD Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Morgan Stanley holds 15,177 shares of HCM stock, worth $228,869. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,177

Previous 17,589 13.71%

Holding current value

$228,869

Previous $264,000 9.47%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$14.83 - $19.21 $35,769 - $46,334	-2,412 Reduced 13.71%	15,177 $239,000
Q2 2025 Aug 15, 2025	SELL	$11.81 - $17.72 $30,788 - $46,196	-2,607 Reduced 12.91%	17,589 $264,000
Q1 2025 May 15, 2025	SELL	$13.09 - $16.75 $82,663 - $105,776	-6,315 Reduced 23.82%	20,196 $303,000
Q4 2024 Feb 14, 2025	SELL	$14.25 - $21.35 $1 Million - $1.5 Million	-70,280 Reduced 72.61%	26,511 $382,000
Q3 2024 May 14, 2025	BUY	$16.03 - $20.31 $207,652 - $263,095	12,954 Added 15.45%	96,791 $1.89 Million

Q3 2024 Nov 14, 2024	BUY	$16.03 - $20.31 $207,652 - $263,095	12,954 Added 15.45%	96,791 $1.89 Million
Q2 2024 May 14, 2025	BUY	$16.36 - $21.78 $937,853 - $1.25 Million	57,326 Added 216.23%	83,837 $1.44 Million
Q2 2024 Oct 17, 2024	BUY	$16.36 - $21.78 $826,523 - $1.1 Million	50,521 Added 151.64%	83,837 $1.44 Million
Q2 2024 Aug 14, 2024	BUY	$16.36 - $21.78 $826,523 - $1.1 Million	50,521 Added 151.64%	83,837 $1.44 Million
Q1 2024 Oct 17, 2024	SELL	$12.08 - $18.56 $610,293 - $937,669	-50,521 Reduced 60.26%	33,316 $559,000
Q1 2024 Aug 16, 2024	SELL	$12.08 - $18.56 $54,915 - $84,373	-4,546 Reduced 12.01%	33,316 $559,000
Q1 2024 May 15, 2024	SELL	$12.08 - $18.56 $54,915 - $84,373	-4,546 Reduced 12.01%	33,316 $559,000
Q4 2023 Aug 16, 2024	SELL	$16.25 - $20.23 $747,093 - $930,074	-45,975 Reduced 54.84%	37,862 $685,000
Q4 2023 Feb 13, 2024	SELL	$16.25 - $20.23 $135,135 - $168,232	-8,316 Reduced 18.01%	37,862 $685,000
Q3 2023 Nov 15, 2023	BUY	$11.85 - $16.95 $32,611 - $46,646	2,752 Added 6.34%	46,178 $782,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $17.73 $316,716 - $520,907	-29,380 Reduced 40.35%	43,426 $521,000
Q1 2023 May 15, 2023	SELL	$13.02 - $19.87 $952,894 - $1.45 Million	-73,187 Reduced 50.13%	72,806 $947,000
Q4 2022 Feb 14, 2023	SELL	$7.65 - $15.51 $761,993 - $1.54 Million	-99,607 Reduced 40.56%	145,993 $2.16 Million
Q3 2022 Nov 14, 2022	BUY	$8.63 - $15.52 $99,831 - $179,535	11,568 Added 4.94%	245,600 $2.18 Million
Q2 2022 Oct 27, 2022	BUY	$8.59 - $20.77 $403,704 - $976,127	46,997 Added 25.13%	234,032 $2.96 Million
Q2 2022 Aug 15, 2022	BUY	$8.59 - $20.77 $403,704 - $976,127	46,997 Added 25.13%	234,032 $2.96 Million
Q1 2022 Oct 27, 2022	SELL	$15.52 - $35.65 $729,393 - $1.68 Million	-46,997 Reduced 20.08%	187,035 $3.54 Million
Q1 2022 May 13, 2022	BUY	$15.52 - $35.65 $110,052 - $252,794	7,091 Added 3.94%	187,035 $3.54 Million
Q4 2021 Feb 14, 2022	SELL	$28.89 - $35.33 $2.22 Million - $2.71 Million	-76,680 Reduced 29.88%	179,944 $6.31 Million
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $9.15 Million - $11 Million	256,624 New	256,624 $9.4 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

5.74M

Call Options Held

Put Options Held

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.61B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account